Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy
Practical Radiation Oncology · 2026-11 · 16 (6) · e512-e523
DOI: 10.1016/j.prro.2026.04.007 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Practical Radiation Oncology, 2026-11. Verfasst von Jiayi Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Canc…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation, Peking University, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
PURPOSE: A phase 3 trial has shown that high-dose, accelerated, hyperfractionated, twice-daily thoracic radiation therapy (54 Gy in 30 fractions) is clinically effective for patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- School of Basic Medical Sciences, Capital Medical University, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address:…
- State Key Laboratory of Molecular Oncology, Beijing, Key Laboratory of Carcinogenesis and Translational Research, Department of Thoracic Surgery I, Peking University Cancer Hospital & Institute, Beijing, China. Electron…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: anhuido…
Förderung
- Wu Jieping Medical Foundation
- Peking University
- Fundamental Research Funds for the Central Universities
- Beijing Nova Program
Zitieren
APA
Yu, J., Zhang, J., Chang, X., Yang, D., Shan, J., Jiang, L., Long, L., Teng, Y., Dong, X., Yu, R., Yu, H., Zhao, J., Ma, S., & Shi, A. (2026). Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy. Practical Radiation Oncology, 16(6), e512-e523. https://doi.org/10.1016/j.prro.2026.04.007
Vancouver
Yu J, Zhang J, Chang X, Yang D, Shan J, Jiang L, et al. Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy. Practical Radiation Oncology. 2026;16(6):e512-e523. doi:10.1016/j.prro.2026.04.007
BibTeX
@article{Yu2026,
author = {Yu, Jiayi and Zhang, Jingwei and Chang, Xiao and Yang, Dan and Shan, Jiahui and Jiang, Leilei and Long, Liuhua and Teng, Yue and Dong, Xin and Yu, Rong and Yu, Huiming and Zhao, Jun and Ma, Shaohua and Shi, Anhui},
title = {Real-World Clinical Outcomes in Patients With Limited-Stage Small Cell Lung Cancer Who Received High-Dose Hyperfractionated Simultaneous Integrated Boost Radiation Therapy Versus Standard-Dose Radiation Therapy},
journal = {Practical Radiation Oncology},
year = {2026},
volume = {16},
number = {6},
pages = {e512--e523},
doi = {10.1016/j.prro.2026.04.007}
}
EUVIMED